|
|
- MHRA (Medicines) Drug Alerts (Various Recipients)
- Other contacts
- Independent Healthcare Providers (registered with CAS)
- Clinical Commissioning Groups
- NHS Regional Offices
- NHS Foundation Trusts (England) - Medical Director
- NHS Foundation Trusts (England) - Chief Executive
- NHS Trusts (England) - Medical Director
- CMO Urgent Messages - Non-NHS Recipients on Public Health Link
- MHRA (Medicines) Drug Alerts - Non-NHS Recipients
- Territorial CMOs in Northern Ireland, Scotland & Wales
- Regional Directors of Public Health
- Consultants in Communicable Diseases
- CMO Urgent Messages - Recipients on Public Health Link
- Director of Public Health
- NHS Trusts (England) - Chief Executive
- GP - Locum
- NHS 111 and Out of hours providers
- GP Practices
- Community Pharmacy
- Primary Care Networks
|
| Title: |
|
Antivirals or Neutralising Antibodies for Non-Hospitalised Patients with COVID-19
|
| Broadcast content: |
|
The published policy has been updated, effective from 13 June 2022, to link to the published report of the Independent Advisory Group commissioned by the Department of Health and Social Care (DHSC) to advise on the groups of patients likely to be at highest risk of deterioration, hospitalisation or death from a COVID infection. The report confirms the groups of patients who are potentially eligible for community based COVID treatments under this policy. Clinicians are asked to note that figure 1 of the report refers to adults (aged 18 years and over) and figure 2 refers to children (aged 12-17 years). The updated policy also now confirms that nirmatrelvir/ritonavir (Paxlovid) may be considered as a treatment choice for patients with stage 3 chronic kidney disease (CKD 3), subject to adequate arrangements for dose adjustment.
There are no other material changes to the policy.
|
| Additional information: |
|
NHS England and NHS Improvement Regional Offices: please cascade this alert to community pharmacy
|